Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 10/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA4 | P22748 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.36 |
| ▸ | IDO1 | P14902 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1098958 | 1.00 | PTPN1 (0.44) | PTPN1CYP19A1CYP11B2CA1CA2 | |
| SCHEMBL1096612 | 0.84 | CYP19A1 (0.39) | CYP19A1CYP11B2CA1CA2CA7 | |
| SCHEMBL1096610 | 0.84 | CYP19A1 (0.39) | CYP19A1CYP11B2CA1CA2CA7 | |
| SCHEMBL1098477 | 0.82 | CYP19A1 (0.50) | CYP19A1CYP11B2IDO1 | |
| SCHEMBL1097189 | 0.82 | CYP19A1 (0.50) | CYP19A1CYP11B2IDO1 | |
| SCHEMBL5131315 | 0.81 | CYP11B2 (0.35) | CYP19A1CYP11B2 | |
| SCHEMBL5131309 | 0.81 | CYP11B2 (0.35) | CYP19A1CYP11B2 | |
| SCHEMBL1097094 | 0.78 | IDO1 (0.39) | CYP19A1CYP11B2CYP11B1IDO1 | |
| SCHEMBL1097090 | 0.78 | IDO1 (0.39) | CYP19A1CYP11B2CYP11B1IDO1 | |
| SCHEMBL1098046 | 0.77 | CYP19A1 (0.43) | CYP19A1CYP11B2CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153674-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-04-10 | — | — | US | disclosed |
| US-8153674-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-04-10 | — | — | US | disclosed |
| US-20090182007-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-07-16 | — | — | US | disclosed |
| US-20090182007-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-07-16 | — | — | US | disclosed |
| EP-2001866-A2 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2008-12-17 | — | — | EP | disclosed |
| WO-2007117982-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2007-10-18 | — | — | WO | disclosed |
| WO-2007117982-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090182007-A1 | ORGANIC COMPOUNDS | REN, CYP17A1, HSD17B1 | PTPN1 2301/4885CYP19A1 166/4885CYP11B2 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.